BG-8

BG-8 is a monoclonal antibody that recognises the blood group Lewis^y.

Immunohistochemical expression

Diagnostic utility

• Differentiation of mesotheliomas from adenocarcinomas:

	adenocarcinoma	mesothelioma
Jordan 19891	18/18 (pulmonary adenocarcinomas)	7/30
Battifora 19952	108/125 (various sites of origin; staining was stronger than in the positive mesotheliomas)	10/100 (epithelial or biphasic mesotheliomas)
Riera 19973	187/211 (various sites of origin)	5/57
Wilson 19974	9/9 (pulmonary and ovarian carcinomas)	5/21
Ordonez 20005	114/135 (39/40 lung, 25/25 breast, 26/30 ovary, 9/10 colon, 1/10 kidney, 6/10 thyroid, 8/10 prostate)	3/50
Ordonez 20036	48/50 (all primary lung adenocarcinomas: 21 case >75% of cells stained, 15 cases 50-75% of cells, 7 cases 25-50% of cells, 6 cases 1-25% of cells and 1 cases <1% of cells. Staining cytoplasmic and membranous)	4/60 (all epithelioid mesotheliomas: 2 cases 1-25% of cells and 2 cases <1% of cells.)
Overall	88% (484/548)	11% (34/318)

A systematic review of three studies (consisting of 231 pulmonary adenocarcinomas and 197 epithelioid mesotheliomas) reported sensitivities and specificities of BerEP4 for pulmonary adenocarcinoma of 93% and 93%⁷.

References

¹ Jordan D, Jagirdar J, Kaneko M. Blood group antigens, Lewis^x and Lewis^y in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 1989;135:931-7.

² Battifora H. Diffuse malignant mesothelioma. In Battifora H, McCaughey WTE, eds. Atlas of Tumor Pathology: Tumors of the serosal membranes, page 71, 3rd series fascicle 15, AFIP.

³ Riera, J. R., C. Astengo-Osuna, et al. (1997). "The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval [see comments]." Am J Surg Pathol 21(12): 1409-19.

⁴ Wilson JD, Merino MJ, Harris C et al. Mesothelioma vs adenocarcinma: does immunohsitochemsitry help? Lab Invest 1997;76:174A.

⁵ Ordonez, N. G. (2000). "Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma." Am J Surg Pathol 24(4): 598-606.

⁶ Ordonez, N. G. (2003). "The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma." Am J Surg Pathol 27(8): 1031-51.

⁷ King JE, Thatcher N, Pickering CA, et al. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006; 48:223-32

This page last revised 16.2.2006.

©SMUHT/PW Bishop